Close menu




November 28th, 2024 | 07:30 CET

PRICE SURGE or SELL-OFF: Buy BioNTech? Is Evotec on the verge of a slump? BioNxt Solutions share on the brink of a breakout?

  • Biotechnology
  • Biotech
  • Pharma
Photo credits: BioNTech SE

Price opportunity with BioNxt! If the innovative biotech stock breaks out of its sideways movement since September, a quick 50% gain could be possible. In any case, things are going well operationally. The Company is developing next-generation drug delivery systems. The Evotec share is not for the faint-hearted. After the price jump following the takeover offer, a sharp drop followed. Analysts see the fair value of the biotech company well below the current price. Will takeover speculation continue? The BioNTech share has avoided slipping below EUR 100. Analysts view the data on the breast cancer candidate positively and recommend buying.

time to read: 3 minutes | Author: Fabian Lorenz
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , EVOTEC SE INH O.N. | DE0005664809 , Bionxt Solutions Inc. | CA0909741062

Table of contents:


    BioNxt Solutions: 150% to this year's high!

    A price opportunity at BioNxt! If the innovative biotech stock breaks out of its sideways movement since September, a path to EUR 0.30 would be clear, and a quick 50% price gain would be possible. Reaching this year's January high would mean a 150% increase. While it is uncertain when the stock might hit EUR 0.50, if the positive operational developments of recent months continue, it is likely just a matter of time.

    BioNxt is developing proprietary systems for next-generation sublingual (orodispersible film), transdermal (skin patch) and oral (enteric-coated tablet) drug delivery. The Company aims to use these to improve the therapeutic results of a wide range of active ingredients. The lead drug development program in BioNxt's portfolio for autoimmune neurodegenerative diseases is a proprietary sublingual alternative for the already approved multiple sclerosis (MS) treatment, Cladribine.

    But it does not stop there. Earlier this week, BioNxt provided an overview of the expansion of its product pipeline for innovative drug delivery systems for various autoimmune diseases and a fascinating initiative in the growth market for life-prolonging products. Among other things, the Company is working on repurposing the sublingual formulation of Cladribine (oral thin film or film-or-fuse) for use in myasthenia gravis – a market that is expected to grow to USD 6.7 billion by 2032 (source: Clinical Trials Arena). In the case of this chronic neuromuscular disease, which causes muscle weakness and exhaustion, patients often have difficulty swallowing. BioNxt is also working on a new administration method for the market for rheumatoid arthritis, which is expected to be worth USD 27 billion by 2033. This widespread autoimmune disease causes joint pain, swelling and limited mobility.

    This makes the BioNxt share a compelling entry opportunity at the moment.

    Evotec: Slide to EUR 4?

    Should I buy or sell Evotec? This is a question many investors are currently asking themselves. The German biotech stock has been on a rollercoaster ride and is not for the faint-hearted. Last week, the surprising takeover bid from Halozyme Therapeutics caused a stir. The company, relatively unknown in Germany, wanted to pay EUR 11 per Evotec share. However, the management of the Hamburg-based biotech company was displeased because there had been no contact prior to the offer. As a result, Evotec's management rejected the offer.

    Halozyme Therapeutics did not want it to come to a takeover battle and withdrew the offer. And so the share price fell rapidly again from EUR 10.50 to EUR 8.50 at the end of last week. Analysts at Deutsche Bank had already warned that, in their opinion, the fair value of Evotec shares is closer to EUR 4. This week, the stock has stopped the crash and is trading above EUR 9. Due to the ongoing restructuring, investors can hardly expect positive operational news in the coming months. Only further simmering takeover rumors are likely to cause price jumps in the foreseeable future.

    Buy BioNTech now?

    A takeover of BioNTech is certainly unrealistic. However, the share price has potential due to the operating performance. Similar to the discussed BioNxt, BioNTech also holds promise. At the Mainz-based biotech company, interest is currently focused on BNT327. The study data for this breast cancer candidate are promising. Due to positive analyst comments, the stock was able to avert a slide below the EUR 100 mark in the past few days and is again trading above EUR 110.

    Yesterday, Deutsche Bank reiterated its "Buy" recommendation for BioNTech shares - the analysts of the major German bank rate the data on BNT327 as "Minimally" positive. The target price remains at USD 150, a fair value also identified by the experts at Jefferies. They also rate BioNTech shares as a "Buy".


    There is a lot to suggest that BioNxt's share price will continue to rise: The stock is poised to break out, the operating performance is promising, and the market capitalization is anything but high. By contrast, the Evotec share is currently only being driven by takeover speculation. Given the ongoing restructuring, the current fair value is likely to be below the current price. BioNTech continues to be well positioned. The cash register is full, and so is the pipeline.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Stefan Feulner on November 20th, 2026 | 05:55 CET

    Merck KGaA, BioNxt Solutions and Novartis – A billion-dollar market is being reshaped

    • Biotechnology

    Multiple sclerosis has long been a billion-dollar market. But as established drugs come under pressure from expiring patents, new therapeutic approaches are advancing through clinical development. The focus is not just on better active ingredients, but increasingly on easier ways of administering treatments. A German pharmaceutical group is battling generic competition, a small biotech developer is betting on a new drug delivery format, and a Swiss industry giant has reported promising Phase 3 data. This creates significant opportunities for investors, each with a different risk profile.

    Read

    Commented by Armin Schulz on November 18th, 2026 | 05:30 CET

    Pharma Turnaround Stocks Under Review: Evotec, Vidac Pharma and Novo Nordisk – Restructuring, Clinical Trial Results and Outlook

    • Evotec
    • Vidac Pharma
    • Novo Nordisk
    • Drug discovery
    • Biotech
    • Pharma
    • Cancer
    • Oncology
    • Warburg effect
    • Obesity
    • Diabetes
    • Weight-loss pill

    Between November 4 and 9, three pharma and biotech stocks released news that suggests a turning point. At one, the quarterly loss before exceptional items narrowed; at the second, initial data from a placebo-controlled trial are available; and the third has raised its full-year guidance. These are not yet proof of a lasting turnaround, but they are verifiable signs of progress. If this trajectory can be maintained, hope could soon turn into substance. We therefore take a closer look at Evotec, Vidac Pharma and Novo Nordisk to see which has turnaround potential.

    Read

    Commented by Armin Schulz on November 17th, 2026 | 19:35 CET

    Bayer, Cardiol Therapeutics, Novartis – Biotech stocks and pharmaceutical giants in the race for the heart

    • Bayer
    • Cardiol Therapeutics
    • Novartis
    • Heart disease
    • Asundexian
    • Pharma
    • Pericarditis
    • CardiolRx
    • Leqvio

    Created and Published on Behalf of Cardiol Therapeutics

    Cardiology is one of the most exciting fields in the pharmaceutical industry. Four days in Chicago have shown just how much is happening in cardiovascular medicine. From November 6 to 9, pharmaceutical giants and small biotech companies gathered at the American Heart Association Scientific Sessions annual congress with a shared goal: to improve care for patients with cardiovascular disease. The major players bring experience and capital, while smaller companies often contribute fresh ideas. When a company succeeds in securing regulatory approval, investors stand to benefit. This interplay is precisely what makes the market so interesting for investors. We therefore take a closer look at Bayer, Cardiol Therapeutics, and Novartis.

    Read